Elanco Beats Q3, Raises Full-Year Guidance and Hits 2.9x Leverage Milestone
ELAN sits 24% above its 52-week low of $19.4.
Summary
Elanco reported Q3 2026 revenue of $1.265 billion (up 11%) and adjusted EPS of $0.27, raised full-year guidance, and reached its 2.9x net leverage target ahead of schedule.
Key Events · Earnings and Guidance · ELAN
-
Q3 Revenue Up 11% to $1.265B
Revenue rose 11% reported and 9% organic constant currency, led by Pet Health up 14%; price contributed 4% and volume 5%.
-
Adjusted EPS $0.27, Up 42%
Adjusted net income of $136 million produced adjusted EPS of $0.27 versus $0.19 a year ago; reported net income was $18 million, or $0.04 per share.
-
Full-Year Guidance Raised
Revenue guidance lifted to $5.155-$5.180 billion from $5.090-$5.140 billion, adjusted EBITDA to $1.050-$1.065 billion, and adjusted EPS to $1.17-$1.20.
-
Net Leverage Hits 2.9x Target
Net debt of $3.005 billion against trailing twelve-month adjusted EBITDA of $1.053 billion gives 2.9x, down 0.7x since December 31, 2025, which management says accelerates capital allocation flexibility.
Analysis · ELAN · Life Sciences
The headline beat is real: Q3 revenue of $1.265 billion rose 11% reported and 9% organic constant currency, and adjusted EPS came in at $0.27 versus $0.19 a year ago. Management then raised full-year revenue guidance to $5.155-$5.180 billion and adjusted EPS to $1.17-$1.20. But the balance sheet is the bigger story. Net leverage fell to 2.9x adjusted EBITDA, a 0.7x improvement since December 31, 2025, which management says unlocks accelerated capital allocation flexibility. For a company carrying $3.7 billion of gross debt, hitting that deleveraging target earlier than planned changes what it can do with cash — buybacks, bolt-on deals, or faster debt paydown — and it removes a persistent overhang on the shares. Price growth accelerated to 4% and adjusted gross margin expanded 300 basis points, showing the growth is coming from pricing and mix rather than just volume.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELAN was trading at $24.10 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.8B. The 52-week trading range was $19.40 to $27.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.